vernakalant (Pending FDA Approval)

Brand and Other Names:Brinavess
  • Print

Dosing & Uses

Atrial Fibrillation

IV antiarrhythmic pending FDA approval for rapid conversion of recent onset atrial fibrillation to sinus rhythm

Next:

Pharmacology

Mechanism of Action

Acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion

Prominently blocks certain potassium channels, specifically, the atrial-selective potassium current Iκur

It is also a sodium channel blocker, depending upon heart rate (HR); as HR increases, affinity for the sodium channel increases; additionally, as the HR decreases, vernakalant binding to the sodium channel decreases

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.